News

St. Louis Financial Planners Asset Management, LLC disclosed in a Thursday filing with the SEC that it sold shares of AT&T worth an estimated $3.3 million in the third quarter.

According to a

Shares in Eli Lilly (NYSE: LLY) had risen 13.2% in the week to Friday morning. The move comes at a time when peer Pfizer announced a deal with the Trump administration that gave that pharmaceutical

The biggest risks facing pharmaceutical companies in recent times haven't had to do with clinical trials or winning regulatory approval. Instead, investors have worried about President Donald

Explore the exciting world of Zoetis (NYSE: ZTS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends

AngioDynamics (NASDAQ: ANGO) stock soared 10.5% through 11:25 a.m. ET Thursday after beating on "earnings" (sort of) this morning.

Heading into the report, analysts forecast AngioDynamics would lose

Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early

In today's video, I discuss recent updates impacting Intel (NASDAQ: INTC), Advanced Micro Devices (NASDAQ: AMD), and Nvidia (NASDAQ: NVDA). To learn more, check out the short video, consider

The big draw for most investors with Pfizer (NYSE: PFE) today is likely to be its lofty 7.2% dividend yield. That compares to 1.2% for the S&P 500 index and about 1.3% for the average pharmaceutical

Some investors fear that President Donald Trump's aggressive tariffs will lead to economic troubles such as inflation. While things may or may not turn out that way, it's still a good idea to

The announcement of a new buildout, as well as developments on the political front, were the factors driving up AbbVie (NYSE: ABBV) stock on Wednesday. The pharmaceutical company's shares rose by

Germany-based BioNTech (NASDAQ: BNTX) saw its U.S. listed stock enjoy a mini-pop on Wednesday, and for once this wasn't largely based on the Comirnaty COVID-19 vaccine it developed with Pfizer

Still basking in the glow of a likely advantageous deal it signed with the government the previous day, Pfizer's (NYSE: PFE) stock was extremely healthy on Hump Day. That positive sentiment was

Shares in Novo Nordisk (NYSE: NVO) were up 6% by 11:30 a.m. on Wednesday. The move comes after Pfizer's agreement with the Trump administration raised hopes that other pharmaceutical companies

Pfizer (NYSE: PFE) announced on Tuesday that it had signed an agreement with the White House that will help Americans pay lower prices for prescription drugs and bolster U.S. leadership in

If you were trying to find dividend stocks before the year 2000, the largest companies in the U.S. were a great place to look. Stalwarts like General Electric (today called GE Aerospace), Pfizer

Stocks in the S&P 500 (SNPINDEX: ^GSPC) offer a miserly yield of 1.2% (on average) today. You can do way better than that and still invest in very attractive businesses. To prove that out, just look

Pfizer Inc (NYSE: PFE) closed at $25.48, rising 6.83%. Volume soared to over 153 million shares, nearly 3.5 times its three-month average of 43.3 million.

Indexes advanced modestly, led by

Summit Financial Wealth Advisors, LLC established a new position in Lockheed Martin(NYSE:LMT), acquiring 12,393 shares valued at approximately $5.74 million as of the second quarter ended June 30

One day after announcing a sizable acquisition, Denmark-based biotech Genmab (NASDAQ: GMAB) was doing well on the stock exchange Tuesday. A pair of analysts weighed in with bullish new takes on the

Pfizer (NYSE: PFE) stock was trading 3.6% higher as of 12:01 p.m. ET Tuesday after The Washington Post reported that the Trump administration had struck a deal with the pharmaceutical giant under

Developing GLP-1 medicines is all the rage these days in the pharmaceutical and biotech industries. The market is growing rapidly, and many (if not most) leading drugmakers are looking to capitalize

Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods. What's the best approach to take? Day trading is

Pfizer (NYSE: PFE)'s stock just can't seem to get out of a tailspin. It faces question marks about its future growth, and investors have effectively given up on it. Even though it looks like cheap